drugset / Trial / NCT05411991
Diuretic Treatment in Acute Heart Failure With Volume Overload Guided by Serial Spot Urine Sodium Assessment
Phase 4
Completed
107 enrolled
Vrije Universiteit Brussel
Jessa Hospital · collabRoche Diagnostics GmbH · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a pragmatic, multicenter, interventional, parallel-arm, randomized, open-label trial to investigate whether a diuretic regimen, based on serial assessment of sodium concentration (UNa) on spot urine samples after diuretic administration and with low-threshold use of combination diuretic therapy, improves decongestion versus usual care in acute heart failure (AHF), potentially leading to better clinical outcomes.
Timeline
- Start
- 2022-06-12
- Primary completion
- 2024-07-01
- Completion
- 2024-07-01
Publications
- Background Vanhentenrijk S, Verbeeck J, Kalpakos T, Vandoren V, Braeckeveldt L, L'hoyes W, Choustoulakis E, Roosens B, Tang WHW, Verwerft J, Verbrugge FH. Rationale and Design of the DECONGEST (Diuretic Treatment in Acute Heart Failure With Volume Overload Guided by Serial Spot Urine Sodium Assessment) Study. J Card Fail. 2025 Apr;31(4):651-660. doi: 10.1016/j.cardfail.2024.08.044. Epub 2024 Aug 30.
- Mullens W, Martens P. Contemporary Diuretic Therapies for Acute Heart Failure: Time for a Desalination-Guided Approach? J Card Fail. 2024 May;30(5):737-738. doi: 10.1016/j.cardfail.2024.01.013. Epub 2024 Mar 4. No abstract available.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Acetazolamide | Small molecule | 500 mg | Intravenous |
| Subject | Bumetanide | Small molecule | 2 mg | Intravenous |
| Subject | Bumetanide | Small molecule | 3 mg | Intravenous |
| Subject | Bumetanide | Small molecule | 4 mg | Intravenous |
| Subject | Canrenoate | Small molecule | 200 mg | Intravenous |
| Subject | Chlorthalidone | Other / unclassified | 50 mg | Oral |
| Subject | Chlorthalidone | Other / unclassified | 100 mg | Oral |
| Background | KCl | Unknown | — | Oral |